Journal article
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study
Abstract
e16529
Background: Up to 17% of women with ovarian cancer (OC) develop venous thromboembolism (VTE). LMWH reduces the risk of VTE and may have antineoplastic effects because tissue factor on OC cells stimulates tumor growth. A multicentre, open-label phase II randomized trial was undertaken to identify a potentially efficacious and safe dose of dalteparin to investigate its antineoplastic potential in OC. Methods: Women with …
Authors
Elit L; Lee A; Julian J; Hoskins P; Julian D; Parpia S; Levine M
Journal
Journal of Clinical Oncology, Vol. 27, No. 15_suppl, pp. e16529–e16529
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2009
DOI
10.1200/jco.2009.27.15_suppl.e16529
ISSN
0732-183X